GlassScriptPhysician profile
Seaborn M Hunt
NPI 1700826922
$3,362.76
in general payments reported to CMS, 2019-2025
30 companies · $374 in 2025
The $374 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $928 · 2020: $473 · 2021: $462 · 2022: $446 · 2023: $305 · 2024: $374 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $554.60 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $537.18 | 2019-2021 | |
| Alcon Vision LLC | $308.88 | 2019-2025 | Hydrus Microstent, Rocklatan, Tryptyr |
| Glaukos Corporation | $190.91 | 2019-2025 | Idose, Idosetr, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Sight Sciences, INC. | $187.78 | 2019-2024 | Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $161.75 | 2019-2023 | Cequa |
| Bausch & Lomb Americas INC. | $161.32 | 2022-2025 | Envista Envy Iol, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $157.69 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $153.12 | 2019-2023 | |
| Abbvie INC. | $117.88 | 2022-2025 | |
| Allergan, INC. | $110.14 | 2020-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $102.58 | 2021-2022 | |
| Ocular Therapeutix, INC. | $95.26 | 2023-2024 | Dextenza |
| Nova Eye, INC. | $86.49 | 2024 | |
| Harrow Eye, LLC | $49.15 | 2024-2025 | Vevye |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumibird Medical INC. | $44.88 | 2021 | |
| Shire North American Group INC | $40.38 | 2019 | |
| Biotissue Holdings INC. | $36.91 | 2020-2024 | |
| Aerie Pharmaceuticals, INC. | $35.42 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $34.88 | 2019-2020 | |
| Dompe US, INC. | $32.12 | 2024 | Oxervate |
| Horizon Therapeutics Plc | $27.61 | 2022 | |
| Mallinckrodt Hospital Products INC. | $26.09 | 2022 | |
| Rxsight INC | $23.44 | 2025 | Rxsight Contact Lens, Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| New World Medical,INC. | $22.66 | 2023 | |
| Hologic Sales and Service, LLC | $19.97 | 2024 | Aptima, Thinprep 2000 Processor |
| Rayner Intraocular Lenses Limited | $17.12 | 2022 | |
| Omeros Corporation | $14.18 | 2019 | |
| Alcon Research LLC | $12.37 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seaborn Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.